Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
Compass Pathways (NASDAQ: CMPS) has published results from its COMP004 study, a 52-week observational follow-up of Phase 2 trials evaluating COMP360 psilocybin for treatment-resistant depression (TRD). The study demonstrated that a single 25mg dose of COMP360 maintained antidepressant effects longer compared to lower doses.
Key findings show the median time to depressive event was 92 days for the 25mg group, versus 83 days (10mg) and 62 days (1mg). A post-hoc analysis revealed even more substantial differences, with 189 days for the 25mg group compared to 43 days (10mg) and 21 days (1mg).
The treatment was generally well-tolerated, with three participants reporting treatment emergent serious adverse events deemed unrelated to the study drug. The company expects top-line data from its ongoing Phase 3 COMP005 trial in Q2 2025, with 26-week COMP006 data anticipated in H2 2026.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its upcoming participation in the Stifel Virtual CNS Forum. The company's management will deliver a presentation on March 18th, 2025 at 11:30 am ET.
The presentation will be available through a live audio webcast on the 'Events' page within the Investors section of Compass's website. Interested parties can access a replay of the webcast for up to 30 days after the event.
Compass Pathways (NASDAQ: CMPS) reported its Q4 and full-year 2024 financial results, highlighting ongoing progress in its clinical trials. The company's Phase 3 COMP005 trial for treatment-resistant depression (TRD) remains on schedule, with top-line data expected in Q2 2025.
Financial results show a net loss of $155.1 million ($2.30 per share) for 2024, compared to $118.5 million in 2023. R&D expenses increased to $119.0 million from $87.5 million, while G&A expenses rose to $59.2 million from $49.4 million.
The company's cash position stood at $165.1 million as of December 31, 2024, with an additional $140.4 million net cash raised in Q1 2025. Full-year 2025 net cash used in operating activities is projected between $120-145 million, with funding sufficient through the planned COMP006 26-week data readout in H2 2026.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 3rd, 2025, at 1:10 pm ET.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS), a biotechnology company focused on mental health innovation, has announced it will release its Q4 and full-year 2024 financial results on February 27th, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) on the same day to discuss results and provide updates on recent developments. Investors can access the call through pre-registration, and a live webcast will be available on the company's website. The webcast recording will remain accessible for 30 days in the Investors section.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a presentation on February 12th, 2025, at 8:40 am ET.
Interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS) has appointed Steve Levine, M.D., as Chief Patient Officer in a newly created executive role. Dr. Levine, who has been with Compass since 2020 as Senior Vice President of Patient Access, will focus on embedding patient-centric strategies across the organization and ensuring treatments address unmet clinical care needs.
Dr. Levine is a board-certified psychiatrist with extensive experience in healthcare innovation and access. He previously founded Actify Neurotherapies, developing care delivery models for interventional psychiatry treatments. His academic background includes training at New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He currently serves as an adjunct professor at Rutgers Medical School.
Compass Pathways (NASDAQ: CMPS) has announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (ADSs) and pre-funded warrants for up to 11,044,720 ADSs. Each ADS and pre-funded warrant includes an ADS Warrant with an exercise price of $5.796, representing a 40% premium to the last sale price.
The offering price is set at $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and ADS Warrant. The offering, led by Deep Track Capital, is expected to generate gross proceeds of approximately $150 million, potentially reaching $353 million if all ADS Warrants are exercised.
The proceeds will fund ongoing Phase 3 trials in treatment-resistant depression (COMP005 and COMP006), with data expected in Q2 2025 and H2 2026, respectively. Additionally, funds will accelerate a late-stage PTSD development program and support working capital needs.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 23, 2024. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ, using a modified market capitalization weighted methodology. Index membership requires companies to meet specific criteria including minimum market capitalization and average daily trading volume. The index undergoes annual reconstitution in December.
Compass Pathways (Nasdaq: CMPS), a mental health biotechnology company, has announced its participation in two major investor conferences this December. The company's executive management team will engage in fireside chats at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 10:25am ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:30pm ET. Live audio webcasts will be available for 30 days after the events.